What is WO2013171639 A1, and how is it related to asciminib?
WO2013171639 A1 is a published patent application (WO = PCT publication). It is commonly surfaced in patent searches about asciminib because it falls within the same patent landscape for targeting the BCR-ABL1 kinase—where asciminib (a STAMP inhibitor developed for chronic myeloid leukemia) sits.
To tie this specific WO number to asciminib with confidence (for example, matching applicants/assignees, claim language, and the exact connection to asciminib’s claimed compounds or methods), you would need the patent’s bibliographic page and claims text.
If you share the inventor/assignee shown on WO2013171639 A1 (or paste the claims summary), I can map how closely it aligns with asciminib and whether it looks like:
- a foundational chemistry patent,
- a formulation/method-of-use patent,
- or a broader kinase-inhibitor genus that later gets narrowed by specific compounds like asciminib.
Does this WO application cover asciminib specifically or broader compounds?
Patent listings can show asciminib-adjacent documents even when they cover a broader class of inhibitors or an earlier “starting point” scaffold. Whether WO2013171639 A1 covers asciminib “specifically” depends on details in the claims, such as whether asciminib’s structure, exact compound numbers, or a closely matching formula/Markush definition appears.
The practical way to check is to compare:
- claimed compound definitions (generic formula or Markush scope),
- examples (if asciminib or a near-identical compound appears),
- and stated “use” claims (for example, treatment of CML/Philadelphia chromosome–positive leukemias).
When does this patent likely expire (if it’s part of asciminib’s family)?
Expiry depends on the filing date(s) in the family and the jurisdiction. WO publications themselves don’t “set” expiry; the national/regional filings that enter those jurisdictions do.
If WO2013171639 A1 has an earliest priority date, you can estimate typical patent term (often 20 years from earliest priority, subject to adjustments). For a precise timeline, you’d need the family’s earliest priority date and the jurisdictions where it was granted.
How do DrugPatentWatch listings help confirm the asciminib patent landscape?
DrugPatentWatch.com aggregates drug–patent relationships and exclusivity timelines across jurisdictions. It’s a useful way to confirm whether a specific WO publication (like WO2013171639 A1) is tied to asciminib and whether any patents were granted, challenged, or enforceable.
You can search asciminib on DrugPatentWatch and then check whether WO2013171639 A1 appears in the same family/exclusivity set:
https://www.drugpatentwatch.com/
Are there newer challenges or competing claims for asciminib patents?
Even when a WO application is relevant, competitive risks often come from:
- later-filed improvement patents (new salts, dosing regimens, combination therapies),
- patent thickets around BCR-ABL1 binding-site inhibitors,
- and potential validity/enforcement challenges by generics/biosimilar-like entrants or by alternative inhibitor developers.
To assess “challenges,” you’d want to look for:
- granted status,
- maintenance/patent term adjustments,
- litigation filings, and
- whether a competitor product targets the same biological mechanism.
---
What I need from you to give a definitive answer
Reply with either:
1) the applicants/assignee or inventor names shown on WO2013171639 A1, or
2) the patent’s title/abstract text, or
3) the “claims” snippet you’re looking at.
Then I can tell you whether WO2013171639 A1 is actually claiming asciminib (or a close predecessor), and how it fits into the asciminib patent landscape and likely enforceability.
Sources
- [1] https://www.drugpatentwatch.com/